Skip to main content
Premium Trial:

Request an Annual Quote

Squibb Licenses Acacia Biosciences' Genome Reporter Matrix

Premium

PRINCETON, NJ--Bristol-Myers Squibb announced it will license the use of Acacia Biosciences' proprietary Genome Reporter Matrix, a technology to identify changes in the expression of thousands of genes in the presence of potential therapeutic compounds. Bristol-Myers Squibb will use the matrix to develop pharmaceutical compound profiles that can help researchers understand the therapeutic benefits and potential side effects of compounds, as well as identify novel targets for drug discovery.

The agreement includes an up-front payment for technology evaluation. Acacia will profile a limited number of potential therapeutic compounds for a fixed fee. Elliott Signal, vice-president of applied genomics for Bristol-Myers Squibb, said Acacia's profiling technology adds to his company's ability to enhance existing therapies and develop novel medicines.

Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.